Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Licenses Mammalian RNAi Patent Application from Stanford

Premium

Alnylam said this week that it has co-exclusively licensed from Stanford University the therapeutic rights to a patent application covering RNAi-mediated inhibition of gene expression in mammals, as well as related technology.

The patent application (numbered 20030153519 and filed on July 19, 2002) specifically claims the delivery of an “RNAi agent” — including interfering ribonucleic acid, such as an siRNA or shRNA, or a transcription template thereof, such as a DNA encoding an shRNA — to a non-embryonic mammal “via a hydrodynamic administration protocol.” Also covered under the application are “RNAi agent pharmaceutical preparations for use in subject methods.”

Specific terms of the arrangement were not disclosed.

The deal with Stanford comes less than two months after Alnylam signed separate deals to license patent applications from Cancer Research Technology and MIT related to inhibiting gene expression with dsRNA and drug delivery techniques for nucleic acid compounds, respectively.

Alnylam has been pushing since its inception to establish a firm IP foundation, acquiring German peer Ribopharma in July partly for its patent estate.

 

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.